| Contents per vial | 5 mg |
|---|---|
| Form | Lyophilized powder |
| Packaging | Sealed glass vial |
| Purity | 99 % (HPLC) |
| Storage | 2–8 °C, keep dry and protect from light |
| Molecular formula | C165H269N47O46 |
| Molecular weight | 3647,28 g/mol |
| Sequence or structure | Tyr–D-Ala–Asp–Ala–Ile–Phe–Thr–Gln–Ser–Tyr–Arg–Lys–Val–Leu–Ala–Gln–Leu–Ser–Ala–Arg–Lys–Leu–Leu–Gln–Asp–Ile–Leu–Ser–Arg–Lys(DAC)–NH2 |
| CAS | 446262-90-4 |
| Intended use | For laboratory research only |
About this product
CJC-1295 with DAC is a long-acting GHRH analog designed to prolong stimulation of the growth hormone axis. The DAC part enables binding to albumin and significantly extends the bioavailability of the molecule. Increases in GH and IGF-1 were monitored in human studies. Therefore, research is focused on hormonal regulation, GH pulsatility and subsequent metabolic processes.
What is CJC-1295 WITH DAC?
From a scientific perspective, CJC-1295 WITH DAC represents a substance classified as a synthetic peptide or peptide analog. Its experimental profile is mainly assessed through GH increase, IGF-1 increase, longer signal duration, metabolic and tissue effects of the GH axis, while individual research questions may use different cell, tissue or organismal models. Binding to target structures, subsequent signaling and changes in selected biological indicators are monitored.
Mechanism of action under investigation
CJC-1295 mimics GHRH and activates the GHRH receptor in the pituitary gland. DAC modification prolongs the circulation of the molecule by binding to albumin.
MAIN AREAS OF RESEARCH
• Prolonged increase in growth hormone: CJC-1295 with DAC is a GHRH analog designed to be long-acting, so it is being investigated for a longer-lasting increase in growth hormone concentrations.
• IGF-1: Clinical research in healthy adults has shown a longer-lasting increase in IGF-1, which is among the main downstream signals of the growth hormone axis.
• Prolonged action of DAC: DAC enables binding to albumin and significantly prolongs the biological action of the molecule compared to shorter-lived GHRH analogues.
• GH/IGF-1 axis: CJC-1295 is used to investigate how long-term stimulation of the GHRH receptor changes the hormonal profile of GH and IGF-1 over time.
Research findings to date
Work to date on CJC-1295 WITH DAC addresses areas including increased GH, increased IGF-1, longer signal duration, and the metabolic and tissue effects of the GH axis. Therefore, research is focused on hormonal regulation, GH pulsatility and subsequent metabolic processes.
In studies of CJC-1295, administration site reactions, flushing, headache and hormonal changes related to increases in GH and IGF-1 were monitored.
